November 16, 2007 - DexCom, Inc. (NASDAQ: DXCM) announced that it has received Food and Drug Administration (FDA) approval to calibrate the SEVENTM, its seven-day continuous glucose monitoring system, using any FDA cleared blood glucose meter. With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end of the first quarter of 2008 and upgrade existing patients during the second quarter of 2008... DexCom's Press Release -
Monday, November 26, 2007
DexCom, FDA Approval to Calibrate Its SEVEN Continuous Glucose Monitoring System Using Any FDA Cleared Blood Glucose Meter
November 16, 2007 - DexCom, Inc. (NASDAQ: DXCM) announced that it has received Food and Drug Administration (FDA) approval to calibrate the SEVENTM, its seven-day continuous glucose monitoring system, using any FDA cleared blood glucose meter. With this approval, patients will be able to calibrate the system without using a connection cable. DexCom expects to launch this feature to new patients near the end of the first quarter of 2008 and upgrade existing patients during the second quarter of 2008... DexCom's Press Release -
